The IMPEDE® Embolization Plug, originally designed by researchers in the Department of Biomedical Engineering at Texas A&M University, has won a 2019 R&D 100 Award from R&D World magazine, one of the highest external recognitions that a team could receive for their research impact.
Two researchers from Texas A&M Engineering were recognized for their outstanding contributions to The Texas A&M University System and their respective fields of expertise by the Board of Regents. Dr. Gerard L. Coté was named a Regents Professor and Dr. Marvin Adams received the Regents Fellow Service Award.
A lifesaving device more than 20 years in the making has received clearance from the U.S. Food and Drug Administration. The clearance allows a company, co-founded by Associate Department Head Dr. Duncan Maitland, to begin to market the medical device.
The Department of Biomedical Engineering hosted Biomaterials Day at Texas A&M University on June 1. It marked the ninth annual Biomaterials Day conference in Texas and the fourth time it has been held at Texas A&M.
Researchers in the Texas A&M College of Veterinary Medicine & Biomedical Sciences (CVM) and the Texas A&M College of Engineering have teamed up to begin filling that gap in the biomedical engineering field--that of veterinary medicine-by exploring the possibilities of what can be accomplished when innovative minds come together.
Tokunbo “TJ” Falohun, a graduate student in the Department of Biomedical Engineering at Texas A&M University, recently was granted a National Science Foundation Graduate Research Fellowship, a prestigious award given to graduate students.
Dr. M. Katherine Banks, vice chancellor and dean of engineering, has appointed Dr. Michael J. McShane head of the Department of Biomedical Engineering at Texas A&M University. The appointment will be effective June 1.
When biomedical researchers have a technology they believe can help patients, they want to get it into the clinic as soon as possible. However, some therapies that look promising in the lab are challenging to “scale up” and produce in sufficient quantities to test in a larger group, or eventually make broadly available to patients.